中国药业2024，Vol.33Issue(14)：102-105,4.DOI:10.3969/j.issn.1006-4931.2024.14.025
仑伐替尼及PD-1抑制剂联合经导管动脉栓塞化疗治疗不可切除肝细胞癌临床观察
Clinical Observation of Lenvatinib,PD-1 Inhibitor Combined with Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
摘要
Abstract
Objective To investigate the clinical efficacy of lenvatinib,programmed death-1(PD-1)inhibitor combined with transcatheter arterial chemoembolization(TACE)in the treatment of unresectable hepatocellular carcinoma(uHCC).Methods A total of 106 patients with uHCC admitted to the People's Hospital of Funan County from July 2020 to July 2023 were selected and divided into the control group(32 cases),the drug group(34 cases)and the combined group(40 cases)based on the different treatment regimens.The patients in the three groups were given TACE,TACE+PD-1 inhibitor,TACE+PD-1 inhibitor+lenvatinib respectively,in which the PD-1 inhibitor was one of Sintilimab Injection,Tislelizumab Injection and Camrelizumab for Injection.All three groups were treated for six weeks.Results The disease control rate(DCR)in the combined group was 90.00%,which was significantly higher than 65.63% in the control group and 70.59% in the drug group(P<0.05).After treatment,the alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBiL),α-fetoprotein(AFP),carcinoembryonic antigen(CEA),α-L-fucosidase(AFU),carbohydrate antigen 199(CA199)levels and Quality of Life Questionnaire-Core 30(QLQ-C30)score in the combined group were significantly lower than those in the control group and drug group(P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion Lenvatinib and PD-1 inhibitor combined with TACE can effectively improve liver function,decrease serum tumor biomarker levels,and improve the quality of life in patients with uHCC.关键词
仑伐替尼/程序性死亡受体-1/经导管动脉栓塞化疗/不可切除肝细胞癌/肝功能/肿瘤标志物/生活质量Key words
lenvatinib/programmed death-1/transcatheter arterial chemoembolization/unresectable hepatocellular carcinoma/liver function/tumor marker/quality of life分类
医药卫生引用本文复制引用
张峰,董燕兵,陈方园,牛猛,刘子洋,谈燚..仑伐替尼及PD-1抑制剂联合经导管动脉栓塞化疗治疗不可切除肝细胞癌临床观察[J].中国药业,2024,33(14):102-105,4.基金项目
安徽省教育厅重点项目[2022AH051416]. （）
